ROWASA Drug Patent Profile

When do Rowasa patents expire, and what generic alternatives are available?

Rowasa is a drug marketed by Mylan Speciality Lp and Meda Pharms and is included in two NDAs.

The generic ingredient in ROWASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rowasa

A generic version of ROWASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for ROWASA

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for ROWASA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Speciality Lp	ROWASA	mesalamine	ENEMA;RECTAL	019618-001	Dec 24, 1987	AB	RX	Yes	Yes
Meda Pharms	ROWASA	mesalamine	SUPPOSITORY;RECTAL	019919-001	Dec 18, 1990		DISCN	Yes	No

International Patents for ROWASA

See the table below for patents covering ROWASA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2677095
European Patent Office	2107870
Denmark	2107870
European Patent Office	0279093	CONTAINER FOR A STABILIZED AQUEOUS SOLUTION OF 5-AMINOSALICYLIC ACID
Israel	81799	PACKAGED PHARMACEUTICAL COMPOSITION CONTAINING BISULFITE STABILIZED SOLUTION OF 5-AMINOSALICYCLIC ACID AND METHODS FOR THE PREPARATION THEREOF

ROWASA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Are the Investment Fundamentals and Scenario for ROWASA?

ROWASA (mesalamine), developed by Salix Pharmaceuticals and marketed primarily in the United States, is a treatment for ulcerative colitis. It is marketed as an enema formulation delivering mesalamine directly to the colon, targeting inflammatory bowel disease (IBD). Its market position, patent status, and regulatory approvals shape its investment prospects.

Market Position and Competitive Landscape

ROWASA faces competition from oral mesalamine formulations, other topical therapies, and biologics. The ulcerative colitis market was valued at approximately $4.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5-7% through 2030, driven by increasing prevalence and unmet needs in moderate to severe cases [1].

Key competitors include Conda's Lialda (mesalamine), Pfizer’s Apriso, and newer biologic treatments such as Pfizer's Xeljanz and Bristol-Myers Squibb’s Skyrizi, which target more severe forms of IBD.

Patent and Regulatory Landscape

ROWASA’s patent protections expired or are approaching expiry in the United States, with generic versions entering the market since 2017. This has led to pricing pressure and erosion of market share.

Regulatory status remains stable, with FDA approval for ROWASA’s indications. No significant recent regulatory sanctions or warnings are noted.

Revenue and Sales Dynamics

Sales peaked at around $350 million annually in the mid-2010s. Post-generic entry, revenues declined substantially, reporting around $50 million in 2022, mainly driven by existing stock and brand loyalty in niche segments.

Earnings are affected by generic competition, with margins affected by price erosion. The potential for off-label use or expansion into additional IBD indications could influence future revenues, but no recent approvals have been announced.

R&D and Pipeline Considerations

There is minimal ongoing R&D specifically for ROWASA, given patent expiry and market saturation. Investment interest centers on developing new formulations or combination therapies for mesalamine derivatives or IBD.

Biotech companies are exploring alternative delivery systems that could capture niche markets or replace older formulations like ROWASA.

Investment Scenario Analysis

Scenario 1: Continued Decline

• Impact of patent expiry and generics persists.
• Revenues decline by 10-15% annually over the next 5 years.
• Profit margins compress due to price competition.
• Investment appeal diminishes; low likelihood of recovery without innovation.

Scenario 2: Niche Market Stabilization

• Brand loyalty maintains a niche market among certain clinician segments.
• Revenues stabilize around $30-50 million.
• Opportunities for line extensions or combination therapies could prolong lifecycle.
• Moderate investment appeal; risks of further erosion remain.

Scenario 3: Innovation and Diversification

• Development of new formulations or delivery mechanisms revitalizes sales.
• Entry into expanding IBD markets with biologic or biosimilar competitors.
• Potential licensing or partnership opportunities renew investment interest.
• High risk but potential for growth if innovation materializes.

Key Investment Considerations

• Patent expiration and generic competition have significantly reduced ROWASA’s revenue.
• The overall IBD market is expanding; shift toward biologics changes competitive dynamics.
• Limited pipeline or R&D investments diminish prospects for product renewal.
• Niche positioning could sustain small-scale revenues if managed well.
• Mergers, licensing deals, or reformulation initiatives could influence future valuation.

Key Takeaways

• ROWASA's patent expiry and generic competition have resulted in a revenue decline.
• Market expansion in IBD favors newer therapies over older formulations.
• Limited R&D efforts reduce potential product revitalization.
• Future investments hinge on reformulation, niche targeting, or partnerships.
• The current outlook favors cautious, risk-adjusted valuation implications.

FAQs

Q1: Can ROWASA regain market share with new formulations?

A: Unlikely without significant innovation; the market prefers oral therapies or biologics.

Q2: Does patent expiration doom ROWASA’s future?

A: It leads to revenue erosion; recovery depends on niche markets or reformulation strategies.

Q3: Are there ongoing R&D efforts for mesalamine-based therapies?

A: Limited; most R&D focuses on newer molecules and biologics for IBD.

Q4: How does the rise of biologics influence ROWASA’s prospects?

A: It shifts treatment preference toward biologics, reducing demand for older formulations like ROWASA.

Q5: Is investing in ROWASA viable today?

A: Generally, no for growth; potential exists only in niche or speculative scenarios involving product innovation or licensing.

References

[1] GlobalData. "Inflammatory Bowel Disease Market Report," 2022.